February 4, 2021 by Chain Drug Review
Kenneth Frazier, Merck
Business, Leading Headlines, Pharmacy, Supplier News
KENILWORTH, N.J. — Merck announced that Kenneth Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021. Frazier will continue to serve on Merck’s board of directors as executive chairman, for a transition period to be determined by the board. The Merck board of directors has unanimously elected Robert M. Davis,
January 25, 2021 by Chain Drug Review
COVID-19 vaccines, Merck
Leading Headlines, Pharmacy, Supplier News
KENILWORTH, N.J. — Merck is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and
November 24, 2020 by Chain Drug Review
Dr. Roger Perlmutter, Merck, OncoImmune
Leading Headlines, Pharmacy
KENILWORTH, N.J. — Merck and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments
November 5, 2020 by Chain Drug Review
Dr. Roger Perlmutter, Merck, VelosBio Inc.
Leading Headlines, Pharmacy, Supplier News
KENILWORTH, N.J. — Merck and VelosBio Inc. announced Thursday that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer
June 5, 2020 by Chain Drug Review
Dr. Nicholas Kartsonis, Merck, Recarbrio
Pharmacy, Supplier News
KENILWORTH, N.J. — Merck announced Friday that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by the following susceptible Gram-negative microorganisms.
May 26, 2020 by Chain Drug Review
COVID-19, IAVI, Merck
Leading Headlines, Pharmacy
KENILWORTH, N.J. — Merck and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, today announced a new collaboration to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis
May 26, 2020 by Chain Drug Review
COVID-19, Merck, Themis
Leading Headlines, Pharmacy
KENILWORTH, N.J.— Merck announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a
May 18, 2020 by Chain Drug Review
Matthew Walsh, Merck, Organon & Co., Rachel Stahler
Leading Headlines, Pharmacy
KENILWORTH, N.J. — Merck, known as MSD outside the United States and Canada, announced the appointment of Matthew Walsh and Rachel Stahler as chief financial officer and chief information officer, respectively, for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses. In his new role at Organon, Walsh will
April 27, 2020 by Chain Drug Review
COVID-19, Dr. Roger Perlmutter, Institute for Systems Biology (ISB), Merck, Merck Vaccines
Leading Headlines, Pharmacy
KENILWORTH, N.J. — Merck and the Institute for Systems Biology (ISB), announced on Monday a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of
April 15, 2020 by Chain Drug Review
biosimilar, breast cancer medication, Merck, Ontruzant (trastuzumab-dttb)
Pharmacy, Supplier News
KENILWORTH, N.J. — Merck announced the U.S. launch of Ontruzant (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin. Ontruzant is available in both 150 mg single-dose vials and 420 mg multiple-dose vials. Ontruzant will be introduced in the U.S. at a list price (wholesaler acquisition cost) of approximately $1,325 for the 150 mg
December 9, 2019 by Chain Drug Review
ArQule, Dr. Roger Perlmutter, Merck, oncology
Business, Leading Headlines, Pharmacy
KENILWORTH, N.J. — Merck and ArQule announced Monday that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development
June 13, 2019 by Chain Drug Review
blockchain technology, FDA, IBM, Karim Bennis, Merck, U.S. Drug Supply Chain Security Act (DSCSA), Walmart
Featured Articles, Leading Headlines, Pharmacy, Retail News
BENTONVILLE, Ark. — IBM, KPMG, Merck and Walmart announced Thursday that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed
March 20, 2019 by Chain Drug Review
Dr. David Woodhouse, Dr. Joe Miletich, Inc. (NGM, Merck, NGM Biopharmaceuticals
Leading Headlines, Pharmacy, Supplier News
KENILWORTH, N.J. — Merck and NGM Biopharmaceuticals, Inc. (NGM) Wednesday announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022. The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across
August 17, 2018 by Chain Drug Review
American Diabetes Association, diabetes care, Healthy Interactions, Lisa French, map4health, Matt Petersen, Merck, Paul Lasiuk
Leading Headlines, Pharmacy, Supplier News, Technology
KENILWORTH, N.J. — Healthy Interactions, a global leader in health education, in collaboration with Merck, known as MSD outside the United States and Canada, today announced the launch of map4health – a digital platform and mobile application in the U.S. that was designed to help facilitate and enhance communications between diabetes patients and educators. This technology was